News Grower

Independent coverage of AI, startups, and technology.

Ars Technica Jun 1, 2026 at 20:58 Big Tech Stable Warm

Moderna gets $50 million to develop mRNA Ebola vaccine against Bundibugyo

Amid a raging Ebola outbreak, officials "urgently accelerate development" of vaccines.

Signal weather

Stable

The story has moved beyond the first headline and now acts as a reliable context anchor.

By Beth Mole Original source
Moderna gets $50 million to develop mRNA Ebola vaccine against Bundibugyo

The global health organization Coalition for Epidemic Preparedness Innovations (CEPI) announced Monday that it will "urgently accelerate development" of three vaccine candidates against Bundibugyo ebolavirus (BDBV), pledging a little over $60 million in the effort to extinguish an outbreak currently raging out of control in the Democratic Republic of the Congo. Under the plans, CEPI has committed up to $50 million to US-based Moderna for preclinical development and Phase 1 clinical testing of its mRNA-based BDBV vaccine candidate. The funding will simultaneously allow the company to ramp up manufacturing capabilities and ready large-scale Phase 2/3 trials in the event the vaccine makes it through early testing. The vaccine will use Moderna's mRNA vaccine platform that allowed for rapid development of a COVID-19 vaccine during the pandemic. "[W]e believe our mRNA platform can play an important role in responding rapidly to emerging infectious disease threats," Moderna CEO Stéphane Bancel said in a statement Monday. " We will move with urgency and scientific rigor to support the response and help bring a potential vaccine closer to the communities that need it most."Read full article Comments

Stay on the signal

Follow Moderna gets $50 million to develop mRNA Ebola vaccine against Bundibugyo

Follow this story beyond a single article: new follow-ups, adjacent sources, and the evolving storyline.

We send a confirmation link first, then only meaningful digests.

Story map

Understand this topic fast

A quick entry into the story: why it matters now, who is involved, and where to go next for context.

Why it matters now

This story is still moving and pulling follow-up coverage.
There are already 6 connected articles in the same storyline to continue from here.
The story keeps orbiting around Accelerate, Against Bundibugyo, and Ars Technica, so the entity pages are the fastest way to build context.
Ars Technica already has 4 follow-up stories on the same theme.

Topic constellation

Open the live map for this story

See which entities, story threads, sources, and follow-up articles shape this story right now.

Click nodes to continue

Entity Cluster Article Hub Source

Story timeline

Continue with this story

A short sequence of events and follow-up stories to understand the arc quickly.

Jun 9, 2026 at 21:05 Ars Technica

Starlink charges $10 monthly hardware fee in move away from one-time purchases

Starlink, SpaceX's top moneymaker, also raised service prices by $5 to $10.

Jun 9, 2026 at 20:56 Ars Technica

Locked in heated rivalry with researcher, Microsoft fixes 0-day they disclosed

A separate zero-day also disclosed by Nightmare Eclipse appears to be patched as well.

Jun 9, 2026 at 20:35 Ars Technica

Three key vital signs make up the "urban pulse" of a city

Cities are dynamic, not static grids, and urbanization is a "spiky," cyclical, and asynchronous process.

Jun 9, 2026 at 20:25 Ars Technica

Commonwealth Fusion makes the physics case for its 400 MW reactor

Five peer-reviewed papers update the design and model its expected output.

Jun 9, 2026 at 20:15 Ars Technica

Paramount accuses Netflix of "scorched-earth campaign" against WBD merger

Netflix's response: "Absurd."

Jun 1, 2026 at 20:58 Ars Technica

Moderna gets $50 million to develop mRNA Ebola vaccine against Bundibugyo

Amid a raging Ebola outbreak, officials "urgently accelerate development" of vaccines.

How reliable this looks

Signal and trust for Ars Technica

This source works at a rapid pace: 100% of recent stories land in the hot window, and 0% carry visible search signal.

Trusted

Reliability

92

Freshness

100

Sources in storyline

1

Related articles

More stories that share tags, source, or category context.

More from Ars Technica

Fresh reporting and follow-up coverage from the same newsroom.

Open source page